HK Stock Market Move | SSY GROUP (02005) rose by over 4%. Nonobet acid choline sustained-release capsules have obtained the drug production registration certificate.

SSY GROUP (02005) rose more than 4%, rising 4.49% to 2.56 Hong Kong dollars at the time of publication, with a turnover of 15.7661 million Hong Kong dollars. On the news front, SSY GROUP announced that the group has obtained the drug production registration certificate from the China National Medical Products Administration for the nonobese ethylene choline sustained-release capsules (135mg), which belong to the category of chemical drugs class 4 and is considered to have passed the consistency evaluation. The nonobese ethylene choline sustained-release capsules are mainly used in adults to control diet and reduce triglyceride levels in patients with severe hypertriglyceridemia, as well as for the treatment of primary hypercholesterolemia or mixed dyslipidemia patients. Earlier, SSY GROUP announced that the group's maraviroc has been approved and registered by the China National Medical Products Administration as an active pharmaceutical ingredient for use in marketed preparations, making it the third domestic company to receive approval. Maraviroc is mainly used to treat influenza A and B viruses.